15478-18-9

Basic information

• Product Name: 5-Hydroxy-1H-indole-3-acetic acid methyl ester
• Synonyms: 5-Hydroxy-1H-indole-3-acetic acid methyl ester;methyl 2-(5-hydroxy-1H-indol-3-yl)acetate
• CAS NO: 15478-18-9
• Molecular Formula: C₁₁H₁₁NO₃
• Molecular Weight: 205.21
• Mol File: 15478-18-9.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-Hydroxy-1H-indole-3-acetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Hydroxy-1H-indole-3-acetic acid methyl ester(15478-18-9)
• EPA Substance Registry System: 5-Hydroxy-1H-indole-3-acetic acid methyl ester(15478-18-9)

Safety Data

• Hazardous Substances Data: 15478-18-9(Hazardous Substances Data)

Usage

Description

5-Hydroxy-1H-indole-3-acetic acid methyl ester, also known as Methyl 5-Hydroxy-3-indoleacetate, is an organic compound that serves as an intermediate in the synthesis of various chemical compounds. It is characterized by its ester functional group and plays a crucial role in the pharmaceutical industry due to its involvement in the production of specific drugs and analogues.

Uses

Used in Pharmaceutical Synthesis:
5-Hydroxy-1H-indole-3-acetic acid methyl ester is used as an intermediate in the synthesis of 5-Hydroxyindole-3-acetic Acid-D5 (H953609) for [application reason] the production of labelled analogues in the pharmaceutical industry.
Used in Allergy Treatment:
In the pharmaceutical industry, 5-Hydroxy-1H-indole-3-acetic acid methyl ester is used as an impurity in the production of Chlorpheniramine (C424300), a histamine H1 receptor antagonist that is used to treat allergy symptoms. Its presence in the synthesis process contributes to the development of effective allergy medications.
Used in Research and Development:
5-Hydroxy-1H-indole-3-acetic acid methyl ester is also utilized in research and development for the study of its chemical properties and potential applications in various fields, including drug discovery and chemical synthesis. Its role in the synthesis of specific compounds makes it a valuable compound for scientific exploration and innovation.

Upstream product

• 1953-54-4 indol-5-ol 
• 425640-22-8 (5-hydroxy-1H-indol-3-yl)-oxo-acetic acid methyl ester 
• 67-56-1 methanol 
• 54-16-0 5-Hydroxyindole-3-acetic acid 
• 3471-32-7 4-Methoxyphenylhydrazine 
• 104-94-9 4-methoxy-aniline 
• 925-57-5 methyl 4-hydroxybutanoate 
• 23304-48-5 (5-methoxy-1H-indol-3-yl)acetic acid methyl ester 
• 19501-58-7 4-methoxyphenylhydrazine hydrochloride 
• 13865-19-5 4-oxobutanoic acid methyl ester 

Downstream Products

• 1275597-95-9 [5-[3-(benzooxazol-2-ylmethylamino)propoxy]-1-(4-fluorobenzyl)-1H-indol-3-yl]acetic acid methyl ester 
• 1275597-96-0 [5-[3-(benzooxazol-2-ylmethylamino)propoxy]-1-(4-fluorobenzyl)-1H-indol-3-yl]acetic acid 
• 1275597-97-1 [5-[3-(benzooxazol-2-ylmethylamino)propoxy]-1-(4-chlorobenzoyl)-1H-indol-3-yl]acetic acid methyl ester 
• 3471-31-6 5-methoxy-1H-indole-3-acetic acid 

Relevant articles and documents

PLANT GROWTH REGULATOR

Providing an auxin derivative that can exert its intended effect more efficiently, while reducing any unintended effects. A compound represented by the General Formula (1) having a specific substituent at the 5- and/or 6-position of the auxin indole ring.

(phenoxy)alkoxy-1H-indole derivatives or pharmaceutically acceptable salts thereof, preparation method therof and pharmaceutical composition for use in preventing or treating PPARα, PPARγ and PPARδ related diseases containing the same as an active ingredient

The present invention relates to (phenoxy)alkoxy-1H-indole derivatives or pharmaceutically allowable salts thereof, to a manufacturing method thereof, and to a pharmaceutical composition for preventing or treating PPARandalpha;, PPARandgamma; and PPARanddelta;-related diseases comprising the derivatives or salt thereof as an active ingredient. The (phenoxy)alkoxy-1H-indole derivatives have excellent abilities of activating PPARandalpha;, PPARandgamma; and PPARanddelta;, thereby being used for preventing or treating PPARandalpha;, PPARandgamma; and PPARanddelta;-related diseases of metabolic diseases, cardiovascular system diseases, cancer, inflammation, etc. as a PPAR agonist.COPYRIGHT KIPO 2017

Erythropoietin Expression Promoter

The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.